Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn ...

Pfizer's strength lies in its integrated approach to drug development, from discovery to clinical trials, and finally, ...

Pfizer (NYSE:PFE) received FDA Priority Review to expand HYMPAVZI to younger hemophilia patients and those with inhibitors.

Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...

Pfizer has announced the winners of the INDovation Program 2025, selecting 14 healthtech startups that will each receive grants of Rs 60 lakh along with 18 months of ...

Our Bureau, Bengaluru Friday, February 13, 2026, 12:20 Hrs [IST] ...

Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

For income investors, there are numerous dividend stocks with strong records, stability and growth potential that can generate wealth for you in the long term.

Delivering Integrated Reaction, Crystallization, Filtration, and Drying Solutions for Advanced Semiconductor Materials ...

FLORENCE, CA, UNITED STATES, February 9, 2026 /EINPresswire.com/ -- Helping Professionals Land Interviews and Offers ...

Alvotech (NasdaqGM:ALVO) reported positive clinical trial results for AVT80, its biosimilar candidate to Entyvio. The company also signed supply and commercialization agreements with Sandoz covering ...